Half Of Targeted Indian Hospitals Clear Cel-Sci Phase III Cancer Trial
This article was originally published in PharmAsia News
Executive Summary
Half of participating Indian hospitals have cleared Austria's Cel-Sci to enroll patients for Phase III trials of its Multikine drug to treat head-and-neck cancer